Payment overview · 2025
General Payments
$107,080.88
131 reported records · 4 companies
Healthcare provider profile · identity verified
Jesi Ramone, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BROOKLYN, NY · NPI 1407819907
Verified facts
What the public records show
CMS Open Payments records show Jesi Ramone, MD received $107,080.88 in general payments during 2025 across 131 reported records.
ViiV Healthcare Company accounted for 75.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Biktarvy, Cabenuva, Descovy, Dovato.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Linzess by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 197 claims for Biktarvy by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Descovy as an associated drug or biological on 2032 records involving 589 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Descovy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Jardiance by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CABENUVA as an associated drug or biological on 13941 records involving 3305 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Cabenuva by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DOVATO as an associated drug or biological on 18732 records involving 3540 distinct recipient NPIs. Public Medicare Part D data also shows 164 claims for Dovato by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $80,297.13 | 75.0% | 83 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $13,521.53 | 12.6% | 20 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $13,245.36 | 12.4% | 27 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.86 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $94,077.50 | 37 |
| Travel and Lodging | $9,039.03 | 23 |
| Food and Beverage | $3,964.35 | 71 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CABENUVA Normalized: cabenuva |
Drug | ViiV Healthcare Company | $42,058.13 | 28 | 2025 |
Source payment records
|
|||||
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $22,657.38 | 20 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $13,245.36 | 27 | 2025 |
Source payment records
|
|||||
| RUKOBIA Normalized: rukobia |
Drug | ViiV Healthcare Company | $12,768.36 | 11 | 2025 |
Source payment records
|
|||||
| Yeztugo Normalized: yeztugo |
Drug | Gilead Sciences, Inc. | $7,279.28 | 7 | 2025 |
Source payment records
|
|||||
| Descovy Normalized: descovy |
Drug | Gilead Sciences, Inc. | $6,190.65 | 8 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $35.00 | 2 | 2025 |
Source payment records
|
|||||
| Biktarvy Normalized: biktarvy |
Drug | Gilead Sciences, Inc. | $20.11 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.86 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.86 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Biktarvy biktarvy |
2025 | Biktarvy | 2024 | 197 | exact normalized | Medicare Part D |
| CABENUVA cabenuva |
2025 | Cabenuva | 2024 | 63 | exact normalized | Medicare Part D |
| Descovy descovy |
2025 | Descovy | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| DOVATO dovato |
2025 | Dovato | 2024 | 164 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
197 | 31 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Descovy open payments reported associated product |
CMS Open Payments — General Payments 2032 supporting records · 589 recipient NPIs · example record 1234351196 |
Descovy · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
67 | 23 |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | CABENUVA open payments reported associated product |
CMS Open Payments — General Payments 13941 supporting records · 3305 recipient NPIs · example record 1189508908 |
Cabenuva · 2024 Exact normalized brand match · 1 Part D row |
63 | 13 |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | DOVATO open payments reported associated product |
CMS Open Payments — General Payments 18732 supporting records · 3540 recipient NPIs · example record 1189508902 |
Dovato · 2024 Exact normalized brand match · 1 Part D row |
164 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 271 | 81 |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 197 | 31 |
| Dovato | Dolutegravir Sodium/Lamivudine | 164 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 140 | 29 |
| Amlodipine Besylate | Amlodipine Besylate | 126 | 46 |
| Januvia | Sitagliptin Phosphate | 103 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 93 | 25 |
| Gabapentin | Gabapentin | 92 | 26 |
| Omeprazole | Omeprazole | 83 | 13 |
| Symtuza | Darunavir/Cob/Emtri/Tenof Alaf | 80 | suppressed |
| Nifedipine Er | Nifedipine | 78 | 23 |
| Metformin Hcl | Metformin Hcl | 70 | 23 |
| Jardiance | Empagliflozin | 67 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 65 | 22 |
| Cabenuva | Cabotegravir/Rilpivirine | 63 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 63 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 57 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 54 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 53 | 21 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 52 | suppressed |
| Losartan Potassium | Losartan Potassium | 50 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 46 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 44 | 14 |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 43 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 38 | suppressed |
| Linzess | Linaclotide | 38 | suppressed |
| Allopurinol | Allopurinol | 34 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 31 | suppressed |
| Simvastatin | Simvastatin | 30 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 28 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 26 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 26 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | suppressed |
| Juluca | Dolutegravir/Rilpivirine | 25 | suppressed |
| Meloxicam | Meloxicam | 25 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 25 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Furosemide | Furosemide | 20 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 19 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Lactulose | Lactulose | 18 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 18 | suppressed |
| Odefsey | Emtricitab/Rilpiviri/Tenof Ala | 18 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 16 | suppressed |
| Ozempic | Semaglutide | 16 | suppressed |
| Tivicay | Dolutegravir Sodium | 16 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 13 |
| Terbinafine Hcl | Terbinafine Hcl | 15 | suppressed |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 14 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 14 | suppressed |
| Atazanavir Sulfate | Atazanavir Sulfate | 13 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 13 | suppressed |
| Ritonavir | Ritonavir | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 11 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $107,080.88 · 131 records | ViiV Healthcare Company | APRETUDE, Biktarvy, CABENUVA, DOVATO, Descovy, MAVYRET, MOUNJARO, RUKOBIA, Yeztugo, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Biktarvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error